Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005630 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy and Sargramostim in Treating Patients With Non-small Cell Lung Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00005630: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00005630 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005630, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy and sargramostim in treating patients who have non-small cell lung cancer.
Interventions
- BIOLOGICAL sargramostim
- BIOLOGICAL ras peptide cancer vaccine
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-07 |
| Est. Completion | 2002-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005630
The ClinicalTrials.gov registry entry for NCT00005630 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which sargramostim is the first listed.
NCT00005630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005630 about?
NCT00005630 is a clinical study titled "Vaccine Therapy and Sargramostim in Treating Patients With Non-small Cell Lung Cancer". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy and sargramostim...
What is the current status of trial NCT00005630?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-07. Estimated completion is 2002-05.
What interventions are being tested in trial NCT00005630?
The interventions under investigation include: sargramostim (BIOLOGICAL), ras peptide cancer vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005630?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.